Chinese Patent Medicine Liu Wei Di Huang Wan Combined with Antihypertensive Drugs, a New Integrative Medicine Therapy, for the Treatment of Essential Hypertension: A Systematic Review of Randomized Controlled Trials

Table 5

Analyses of diastolic blood pressure.

Trials		WMD (95% CI)	𝑃 value
LWDHW plus sustained-release nifedipine versus sustained release nifedipine	1	−7.00 (−8.74, −5.26)	<0.00001
LWDHW plus nifedipine controlled release tablet versus nifedipine controlled release tablet	1	−2.25 (−11.90, 7.40)	0.65
LWDHW plus captopril versus captopril	1	−6.75 (−11.26, −2.24)	0.003
LWDHW plus nifedipine controlled release tablet nifedipine controlled release tablet	1	−4.00 (−7.23, −0.77)	0.02
LWDHW plus nifedipine versus nifedipine	1	−6.00 (−14.46, 2.46)	0.16
Meta-analysis	5	−6.27 (−7.69, −4.86)	<0.00001